Abstract：
Human pegivirus-1 (HPgV-1) is known for its protective role in HIV co-infected individuals. This immunomodulatory effect raised questions concerning the possible role of HPgV-1 infection and the risk of rejection in liver transplanted patients. We aimed to evaluate the possible protective effect of HPgV-1 on graft outcome of liver transplanted patients. A total of 283 patients were recruited. Formalin-fixed paraffin-embedded tissue samples were collected from the explanted liver. HBV-DNA, HCV-RNA, and HPgV-1-RNA were determined using PCR and multiplex RT-PCR assays. The clinical course of patients including the occurrence of acute cellular rejection was compared between HPgV-1-infected vs. uninfected patients. HBV-DNA, HCV-RNA and HPgV-1-RNA were detected in 42.6%, 4.9%, and 7.8% of samples, respectively. None of the HPgV-1-infected patients experienced graft rejection. Group LASSO logistic regression revealed that HPgV-1 infection was the only factor which significantly reduced the odds of graft rejection (OR = 0.5, 95% CI = 0.29-0.89). No significant association was found between the presence of HPgV-1 with HBV and HCV infections. The lack of graft rejection in HPgV-1-infected liver transplanted patients might indicate a possible role of this virus for graft surveillance. Since these are still preliminary findings, prospective studies should further elucidate the role of HPgV-1 in liver transplantation outcomes.
摘要：
人类pegivirus-1（HPgV-1）因其在HIV共感染个体中的保护作用而闻名。这种免疫调节作用引起了人们对肝移植患者中HPgV-1感染的可能作用和排斥反应风险的质疑。我们旨在评估HPgV-1对肝移植患者移植物结局的可能保护作用。总共招募了283名患者。从外植的肝脏收集福尔马林固定的石蜡包埋的组织样品。HBV-DNA,HCV-RNA,使用PCR和多重RT-PCR测定和HPgV-1-RNA。在HPgV-1感染与感染之间比较了患者的临床过程，包括急性细胞排斥反应的发生。未感染患者HBV-DNA,HCV-RNA和HPgV-1-RNA的检出率为42.6%,4.9%,和7.8%的样本，分别。没有感染HPgV-1的患者出现移植排斥反应。LASSO组logistic回归分析显示，HPgV-1感染是显著降低移植物排斥反应几率的唯一因素(OR=0.5，95%CI=0.29-0.89)。没有发现与HBV和HCV感染之间的HPgV-1的存在显著关联。HPgV-1感染的肝移植患者缺乏移植物排斥反应可能表明该病毒在移植物监测中的可能作用。由于这些仍然是初步发现，前瞻性研究应进一步阐明HPgV-1在肝移植结局中的作用.
